Pharmaceutical Last week’s notable news continued with a strong focus on the novel coronavirus, with UK respiratory drug developer Synairgen presenting new data on its SNG001 inhaled interferon candidate for hospitalized COVID-19 patients, sending the firm’s shares into the stratosphere. AstraZeneca and Oxford University released encouraging Phase I/II results for their COVID-19 vaccine candidate ChAdOx1/AZD1222. Also, BioNTech and Pfizer released positive COVID-19 vaccine data. Additionally, US biotech Incyte reported strong Phase III results for its graft-versus-host (GVID) drug Jakafi. 26 July 2020